{"id":"https://openalex.org/W1942079596","doi":null,"title":"Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial","display_name":"Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial","publication_year":2012,"publication_date":"2012-09-01","ids":{"openalex":"https://openalex.org/W1942079596","mag":"1942079596"},"language":"en","primary_location":{"id":"mag:1942079596","doi":null,"is_oa":false,"landing_page_url":"http://erj.ersjournals.com/content/erj/40/Suppl_56/P2123.full.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"European Respiratory Journal","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001571542","display_name":"Jan O. L\u00f6tvall","orcid":"https://orcid.org/0000-0001-9195-9249","observed_orcids":["https://orcid.org/0000-0001-9195-9249"]},"institutions":[{"id":"https://openalex.org/I881427289","display_name":"University of Gothenburg","ror":"https://ror.org/01tm6cn81","country_code":"SE","type":"education","lineage":["https://openalex.org/I881427289"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Jan L\u00f6tvall","raw_affiliation_strings":["Krefting Research Centre, University of Gothenburg, , Sweden"],"raw_orcid":"https://orcid.org/0000-0001-9195-9249","affiliations":[{"raw_affiliation_string":"Krefting Research Centre, University of Gothenburg, , Sweden","institution_ids":["https://openalex.org/I881427289"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048656238","display_name":"Eugene R. Bleecker","orcid":"https://orcid.org/0000-0002-4767-3494","observed_orcids":["https://orcid.org/0000-0002-4767-3494"]},"institutions":[{"id":"https://openalex.org/I4405269449","display_name":"Wake Forest University Health Sciences","ror":"https://ror.org/046r1r105","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]},{"id":"https://openalex.org/I47251452","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724","country_code":"US","type":"education","lineage":["https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eugene R. Bleecker","raw_affiliation_strings":["Center for Genomics and Personalized Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, United States"],"raw_orcid":"https://orcid.org/0000-0002-4767-3494","affiliations":[{"raw_affiliation_string":"Center for Genomics and Personalized Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, United States","institution_ids":["https://openalex.org/I4405269449","https://openalex.org/I47251452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044980958","display_name":"William W. Busse","orcid":"https://orcid.org/0000-0003-2591-4696","observed_orcids":["https://orcid.org/0000-0003-2591-4696"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William W. Busse","raw_affiliation_strings":["Department of Medicine, University of Wisconsin, Madison, WI, United States"],"raw_orcid":"https://orcid.org/0000-0003-2591-4696","affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Wisconsin, Madison, WI, United States","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026242254","display_name":"Paul M. O\u2019Byrne","orcid":"https://orcid.org/0000-0003-0979-281X","observed_orcids":["https://orcid.org/0000-0003-0979-281X"]},"institutions":[{"id":"https://openalex.org/I76442945","display_name":"Hamilton Health Sciences","ror":"https://ror.org/02dqdxm48","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I76442945"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Paul M. O\u2019Byrne","raw_affiliation_strings":["Department of Medicine, Michael G DeGroote School of Medicine, Hamilton, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Michael G DeGroote School of Medicine, Hamilton, ON, Canada","institution_ids":["https://openalex.org/I76442945"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028344690","display_name":"Ashley A. Woodcock","orcid":"https://orcid.org/0000-0002-5428-8578","observed_orcids":["https://orcid.org/0000-0002-5428-8578"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ashley Woodcock","raw_affiliation_strings":["School of Translational Medicine, University of Manchester, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-5428-8578","affiliations":[{"raw_affiliation_string":"School of Translational Medicine, University of Manchester, United Kingdom","institution_ids":["https://openalex.org/I28407311"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090062530","display_name":"Eric Donn Bateman","orcid":"https://orcid.org/0000-0002-5064-5849","observed_orcids":["https://orcid.org/0000-0002-5064-5849"]},"institutions":[{"id":"https://openalex.org/I157614274","display_name":"University of Cape Town","ror":"https://ror.org/03p74gp79","country_code":"ZA","type":"education","lineage":["https://openalex.org/I157614274"]}],"countries":["ZA"],"is_corresponding":false,"raw_author_name":"Eric D. Bateman","raw_affiliation_strings":["Department of Medicine,* University of Cape Town, South Africa"],"raw_orcid":"https://orcid.org/0000-0002-5064-5849","affiliations":[{"raw_affiliation_string":"Department of Medicine,* University of Cape Town, South Africa","institution_ids":["https://openalex.org/I157614274"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025257736","display_name":"Edward Kerwin","orcid":"https://orcid.org/0000-0002-1697-9036","observed_orcids":["https://orcid.org/0000-0002-1697-9036"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edward Kerwin","raw_affiliation_strings":["Allergy & Asthma Center, Clinical Research Institute of Southern Oregon, Medford, OR, United States"],"raw_orcid":"https://orcid.org/0000-0002-1697-9036","affiliations":[{"raw_affiliation_string":"Allergy & Asthma Center, Clinical Research Institute of Southern Oregon, Medford, OR, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002295744","display_name":"Sally Stone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sally Stone","raw_affiliation_strings":["Respiratory Medicine Development Centre, GlaxoSmithKline, Uxbridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Respiratory Medicine Development Centre, GlaxoSmithKline, Uxbridge, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064031726","display_name":"Richard Forth","orcid":"https://orcid.org/0000-0002-1896-8808","observed_orcids":["https://orcid.org/0000-0002-1896-8808"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Forth","raw_affiliation_strings":["Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, Durham, NC, United States"],"raw_orcid":"https://orcid.org/0000-0002-1896-8808","affiliations":[{"raw_affiliation_string":"Quantitative Sciences Division, GlaxoSmithKline, Research Triangle Park, Durham, NC, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036067413","display_name":"Loretta Jacques","orcid":"https://orcid.org/0000-0001-7293-3246","observed_orcids":["https://orcid.org/0000-0001-7293-3246"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loretta Jacques","raw_affiliation_strings":["Respiratory Medicine Development Centre, GlaxoSmithKline, Uxbridge, United States"],"raw_orcid":"https://orcid.org/0000-0001-7293-3246","affiliations":[{"raw_affiliation_string":"Respiratory Medicine Development Centre, GlaxoSmithKline, Uxbridge, United States","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4025,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.64002101,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"40","issue":null,"first_page":"2123","last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluticasone-furoate","display_name":"fluticasone furoate","score":1.0},{"id":"https://openalex.org/keywords/persistent-asthma","display_name":"persistent asthma","score":0.8399999737739563},{"id":"https://openalex.org/keywords/fluticasone-propionate","display_name":"fluticasone propionate","score":0.9789999723434448},{"id":"https://openalex.org/keywords/dry-powder-inhaler","display_name":"dry powder inhaler","score":0.8650000095367432},{"id":"https://openalex.org/keywords/fev1","display_name":"FEV1","score":0.7749999761581421},{"id":"https://openalex.org/keywords/urinary-cortisol","display_name":"urinary cortisol","score":0.8500000238418579},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8040000200271606},{"id":"https://openalex.org/keywords/asthma-exacerbations","display_name":"asthma exacerbations","score":0.6740000247955322},{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.36500000953674316}],"concepts":[{"id":"https://openalex.org/C2779028295","wikidata":"https://www.wikidata.org/wiki/Q8564098","display_name":"Fluticasone propionate","level":3,"score":0.9570152759552002},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9461138248443604},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.790981113910675},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.6970392465591431},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6063033938407898},{"id":"https://openalex.org/C2780261241","wikidata":"https://www.wikidata.org/wiki/Q1394363","display_name":"Inhaler","level":3,"score":0.589956521987915},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5579666495323181},{"id":"https://openalex.org/C2777419714","wikidata":"https://www.wikidata.org/wiki/Q1334805","display_name":"Dry-powder inhaler","level":4,"score":0.551797091960907},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5200419425964355},{"id":"https://openalex.org/C2776476923","wikidata":"https://www.wikidata.org/wiki/Q7725","display_name":"Evening","level":2,"score":0.5033456683158875},{"id":"https://openalex.org/C2776804153","wikidata":"https://www.wikidata.org/wiki/Q210420","display_name":"Corticosteroid","level":2,"score":0.48354315757751465},{"id":"https://openalex.org/C2779871671","wikidata":"https://www.wikidata.org/wiki/Q637247","display_name":"Formoterol","level":4,"score":0.4584561884403229},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.330113023519516},{"id":"https://openalex.org/C2776136866","wikidata":"https://www.wikidata.org/wiki/Q422212","display_name":"Budesonide","level":3,"score":0.2743217945098877},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.258465975522995},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C1276947","wikidata":"https://www.wikidata.org/wiki/Q333","display_name":"Astronomy","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1942079596","doi":null,"is_oa":false,"landing_page_url":"http://erj.ersjournals.com/content/erj/40/Suppl_56/P2123.full.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"European Respiratory Journal","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2077456532","https://openalex.org/W2108545239","https://openalex.org/W1961335309","https://openalex.org/W2091295600","https://openalex.org/W2171365228","https://openalex.org/W1963853409","https://openalex.org/W2118866729","https://openalex.org/W1991683671","https://openalex.org/W2062765710","https://openalex.org/W6958401080"],"abstract_inverted_index":{"Introduction:":[0],"The":[2],"inhaled":[3],"corticosteroid":[4],"(ICS)":[5],"FF":[6,43,81,151,179,192,216],"is":[7],"under":[8],"development":[9],"as":[10],"a":[11,53,88,202,221],"OD":[12,21,83,194],"monotherapy":[13],"for":[14,28,105,178],"asthma":[15,29,50],"and":[16,30,40,141,152,166,181,209,225],"in":[17,44,84,123],"combination":[18],"with":[19,48,161,220],"the":[20,38,85],"long-acting":[22],"beta":[23],"2":[24],"agonist":[26],"vilanterol":[27],"COPD.":[31],"Objectives:":[34],"To":[36],"evaluate":[37],"efficacy":[39],"safety":[41],"of":[42,57,138],"patients":[45,77],"\u226512":[46],"years":[47],"persistent":[49],"uncontrolled":[51],"on":[52,227],"stable":[54],"low-to-mid":[55],"dose":[56],"ICS":[58],"(\u2264500mcg":[59],"fluticasone":[60],"propionate":[61],"[FP]":[62],"equivalent":[63],"total":[64],"daily":[65,97],"dose).":[66],"Methods:":[69],"In":[71],"this":[72],"double-blind,":[73],"double-dummy,":[74],"placebo-controlled":[75],"study,":[76],"(N=343;":[78],"ITT)":[79],"received":[80],"(100mcg":[82],"evening":[86],"via":[87,99],"new":[89],"dry":[90],"powder":[91],"inhaler;":[92],"n=114),":[93],"FP":[94,153,182,206],"(250mcg":[95],"twice":[96],"[BD]":[98],"DISKUS\u2122;":[100],"n=114)":[101],"or":[102],"placebo":[103,162,185],"(n=115)":[104],"24":[106,115,129],"weeks.":[107,116,130],"Primary":[108],"endpoint:":[109,119],"trough":[110,156,197],"FEV":[111,157,198],"1":[112,158,199],"at":[114],"Powered":[117],"secondary":[118],"change":[120],"from":[121],"baseline":[122],"%":[124,172],"rescue-free":[125,173],"24h":[126,142,174,228],"periods":[127,175],"over":[128],"Safety":[131],"assessments":[132],"included":[133],"adverse":[134],"events":[135],"(AEs),":[136],"incidence":[137],"severe":[139],"exacerbations":[140],"urinary":[143],"cortisol":[144],"(UC)":[145],"excretion.":[146],"Results:":[149],"significantly":[154,195],"improved":[155,196],"compared":[160],"(diff.":[163],"146mL":[164],"[p=0.009]":[165],"145mL":[167],"[p=0.011],":[168],"respectively).":[169],"Significantly":[170],"more":[171],"were":[176],"reported":[177],"(14.8)":[180],"(17.9)":[183],"than":[184],"(both":[186],"p":[187],"Conclusions:":[190],"100mcg":[193],"to":[201,205,214,230],"similar":[203,222],"extent":[204],"250mcg":[207],"BD":[208],"reduced":[210],"rescue":[211],"use":[212],"relative":[213],"placebo.":[215],"was":[217],"well":[218],"tolerated":[219],"AE":[223],"profile":[224],"effect":[226],"UC":[229],"FP.":[231],"Funded":[233],"by":[234],"GSK":[235],"(FFA112059;":[236],"NCT01159912).":[237]},"counts_by_year":[{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}